

PROPHYLACTIC AND THERAPEUTIC EFFECTS OF ALLICIN AGAINST GOATS EXPERIMENTALLY INFECTED WITH COLIBACILLOSIS

Noura E. Attia¹, Yasmin H. Bayoumi¹, Mosa M. Bahnass², Amany Behairy³, Elshaima M. Fawzi^{2*}

¹Internal Medicine, ²Infectious Diseases, Department of Animal Medicine, ³Department of Physiology, Faculty of Veterinary Medicine, Zagazig University 44511, Zagazig, Sharkia, Egypt

*Corresponding author, E-mail: elshaimafawzi@yahoo.es, a.fawzy@zu.edu.eg

Abstract: The current investigation was carried out to evaluate the prophylactic and therapeutic effects of allicin against goats experimentally infected with *Escherichia coli* (*E. coli*). Twelve native breed goats, one year old, belonging to the private farms of Faculty of Veterinary Medicine, Zagazig University, Egypt, were used in this study. The animals were divided into three groups (4 goats each); prophylactic group (G1) received allicin “2.7 mg/kg twice daily” then infected with *E. coli*, treatment group (G2) was experimentally infected with *E. coli*, then received the above mentioned allicin dose and lastly untreated control group (G3) were remained without any interference. All goats were exposed to complete and comprehensive clinical examination. Blood samples were collected from jugular veins of goats to determine blood pictures and some selective parameters. Clinical investigation of goats revealed a significant increase of mean rectal temperature, heart and respiration rates on the 7th day in G2 till the 28th day. Hematological analysis showed that oral administration of allicin had no significant effect on the hematological parameters, hemoglobin (Hb), red blood cells (RBCs) and packed cell volume (PCV)”. A significant increase in white blood cells (WBCs) and neutrophils on the 7th, 14th, 17th and 28th days in both treated groups was observed. Biochemical analysis showed significant increase of malondialdehyde (MDA) levels in both groups following *E. coli* inoculation then decreased significantly till returned to the normal range on the 28th day. Total antioxidant capacity (TAC) was increased significantly on the 7th day in G1 but it significantly decreased in G2 during the same period then increased significantly on both groups till the 28th day. Immunological results showed marked increase in both research treated groups. Allicin administration increase the release of interleukin-6 (IL-6), interleukin- 12 (IL-12) and tumor necrosis factor-alpha (TNF- α) in both infected groups than in the untreated control one.

Key words: Allicin; antioxidant; colibacillosis; goats; immunoglobulins

Introduction

Small ruminant production, sheep and goats, plays an important role in livestock development, particularly in developing countries like Egypt. It was increased recently due to lower feeding costs and other management practices. Goats are able to produce milk, meat and hair even in harsh environments (1). Low milk and meat production from goats is due to poor genetic composition and poor nutritional status (2).

As possible alternatives to growth promoters, aromatic plants and their extracts have increased

attention in recent years. Garlic (*Allium sativum*) has been used since ancient times in folk medicine (3). *Allium sativum* is a member of the family *Liliaceae*. Bioactive garlic ingredients include several sulfur-containing compounds such as alliin, diallyl sulphide (DAS) and allicin (4).

Allicin (diallylthiosulfinate) has many therapeutic properties, but it is probably the most commonly scientifically researched that it has anti-microbial activity against many pathogenic microbes as *Bacillus* spp., *Escherichia coli* (*E. coli*), *Mycobacterium* spp., *Pseudomonas* spp., *Staphylococcus* spp. and *Streptococcus* spp. (5). This anti- microbial

effect of allicin is thought to be due to its oxidative interaction with important thiol-containing enzymes (6). In addition to its antimicrobial effect, garlic is a natural antioxidant and has antihypertensive properties (3). Furthermore, garlic extract treatment has been shown to enhance the activation role of T-lymphocytes, natural killer cells, interleukins and improving the immune responses (3).

Colibacillosis is one of the significant diseases caused by pathogenic serotypes of *E. coli* in farm animals (7). Two types of infections have been associated with *E. coli*, enteric and septicemic infections. The enteric type is distinguished by varying degrees of diarrhea, dehydration, and elevated mortality in untreated cases (8). The pathophysiology of colibacillosis is due to K99 + adhesin antigen and heat stable enterotoxin, the major virulence attributes of enteric strain of *E. coli* in farm ruminants (9). It is a significant cause of economic loss in raising sheep and goat and is one of the important zoonotic diseases (10). The cell wall of Gram-negative bacteria contains endotoxin; the major biologically active component of the endotoxin is lipopolysaccharide (LPS), which is a potent inducer of inflammation (11).

Plant extracts and essential oils were evaluated frequently against bacteria (12, 13). Garlic has long been considered the most effective plant for treating bacterial infections. Allicin is a garlic defense molecule that has broad antimicrobial activities against both Gram-positive and Gram-negative bacteria (14). Thus, the objective of this study was to investigate the effects of oral allicin administration as a prophylactic and treatment natural agent against the experimental infection of goats with *E. coli* by estimating the blood profile and some biochemical parameters, which reflect the oxidative stress and the immunological status of the animals.

Materials and methods

Ethical approval

The study was approved by the Institutional Animal Care and Use Committee (IACUC), Zagazig University (Approval No. ZU-IACUC/2/F/121/2021).

Bacterial strain

Non-verotoxigenic strain of *E. coli* O157 was kindly provided by Department of Microbiology, Faculty of Veterinary Medicine, Zagazig

University to be used for the experimental infection with a concentration of 2×10^9 colony-forming units (CFU) / mL prior to inoculation (15).

Antibacterial agent

Allicin Max™ capsule (180 mg allicin powder/capsule) obtained from Allicin International Ltd, Rye, East Sussex, UK was administered orally to the animal.

Experimental design, animal management and feeding regime

The experiment was carried out on Baladi goats at Faculty of Veterinary Medicine Farm, Zagazig University, Egypt. The study lasted 70 days, from November 2020 to January 2021. Twelve clinically-normal, non-pregnant female native-breed goats of one-year age weighing 30 ± 2 kg were included in this study. The goats have been randomly divided into three groups (G1, G2 and G3); each consists of four animals. The animals were housed for 15 days to acclimatize and were monitored during this period. Each group ($n = 4$) was reared in the same pen during the whole experiment period.

Goats in G1 received 2.7 mg/kg of allicin twice a day at 12-h intervals for seven consecutive days after dissolving it in normal saline as a prophylactic dose (16). The animals were then experimentally infected with the above mentioned dose of *E. coli* O157 strain. After seven days, we evaluated animals' conditions and clinical symptoms. Group 2 was experimentally infected with *E. coli* and the animal state and clinical signs were observed for seven days. Thereafter, the animals were administered the allicin orally for seven consecutive days after dissolving in normal saline as treatment dose of 2.7 mg/kg twice daily with 12-h intervals (16). The remaining G3 was kept as a control without interference. During the experimental period, the animals were maintained on forage and concentrate supplements at a ratio of 70:30. The animals were fed twice a day with a commercial goat pellet concentrate. All animals were fed green fodder "Barseem" when was available.

Blood sampling

Two blood samples were collected from each selected animal via jugular vein puncture. For hematological studies, 2 mL of blood was taken into

Table 1: The effect of allicin supplement as prophylactic or treatment in goats experimentally infected with *E. coli* 0157 on vital signs

Parameter	Group 1	Group 2	Group 3	P-value
Temp (°C) / day				
0	39.00 ± 0.058	39.13 ± 0.120	39.10 ± 0.058	0.54
7 th	39.27 ± 0.176 ^b	41.23 ± 0.145 ^a	39.33 ± 0.088 ^b	< 0.001
14 th	39.47 ± 0.145 ^b	40.17 ± 0.203 ^a	39.17 ± 0.145 ^b	0.014
17 th	39.43 ± 0.033 ^a	39.53 ± 0.088 ^a	39.13 ± 0.067 ^b	0.013
28 th	39.23 ± 0.033	39.13 ± 0.120	39.20 ± 0.153	0.824
42 th	39.10 ± 0.058	39.23 ± 0.120	39.13 ± 0.067	0.555
56 th	38.97 ± 0.033 ^b	39.13 ± 0.088 ^{ab}	39.23 ± 0.033 ^a	0.045
HR/min / day				
0	85.00 ± 1.528	83.33 ± 2.028	84.00 ± 0.577	0.744
7 th	84.33 ± 1.333 ^b	104.0 ± 3.786 ^a	85.33 ± 0.882 ^b	0.002
14 th	95.33 ± 0.882 ^a	100.0 ± 2.887 ^a	85.33 ± 1.453 ^b	0.005
17 th	93.33 ± 0.882 ^a	98.00 ± 2.887 ^a	84.67 ± 0.882 ^b	0.006
28 th	90.67 ± 0.667	92.00 ± 3.055	85.67 ± 1.333	0.132
42 th	88.00 ± 0.577	89.67 ± 2.728	83.33 ± 0.882	0.087
56 th	84.67 ± 0.333	87.33 ± 1.333	84.33 ± 0.333	0.077
Resp./min / day				
0	24.00 ± 0.577	24.67 ± 0.882	23.33 ± 1.667	0.723
7 th	29.67 ± 0.333 ^b	37.33 ± 1.453 ^a	23.00 ± 0.577 ^c	< 0.001
14 th	28.00 ± 0.577 ^b	34.67 ± 1.453 ^a	24.00 ± 0.577 ^c	0.001
17 th	26.00 ± 0.577 ^b	32.00 ± 1.155 ^a	24.00 ± 0.577 ^b	0.001
28 th	24.00 ± 0.577	27.33 ± 1.202	24.00 ± 1.000	0.079
42 th	24.67 ± 0.333	26.00 ± 0.577	24.33 ± 0.333	0.072
56 th	24.00 ± 0.577	25.33 ± 0.882	25.00 ± 0.577	0.422

Values are represented as mean ± SEM. Means within the same row carrying different superscripts (a, b, and c) are significant at $p < 0.05$. Temperature (Temp), heart rate (HR), respiration (Resp)

potassium ethylene diamine tetra-acetic acid (k2 EDTA) tubes. The other blood sample of 10 mL was taken in plain tubes without anticoagulant, allowed to stand at room temperature for 2 h, then the serum was separated by centrifugation at 10000 rpm/10 minutes, as previously described (17). The blood samples were taken from the three groups before starting of the experimental design. Moreover, blood sampling was repeated twice on 7th and 14th day of the experiment. The fourth blood samples were taken after 72 h from end of experiment then on 28th, 42th and 56th days post experiment. Blood samples from the control group were included in each time interval.

Hematobiochemical screening

A complete blood picture was determined using an automated blood cell analyzer (Sysmex XT-2000iV, Kobe, Japan). Total proteins (TP)

and albumin (Alb), were measured using commercial diagnostic kits obtained by Biomerieux, Spain. Serum globulins were calculated mathematically by subtracting albumin from total proteins (17).

Malondialdehyde (MDA) was assessed using Cusabio Biotech's ELISA Kits (Cusabio Biotech inc, Houston, Texas USA). Serum total antioxidant capacity (TAC) was determined using Bio diagnostic kits (Cusabio Biotech inc, Houston, Texas USA) (18). The determination of immunoglobulins (IgA, IgM, and IgG) was conducted according to Toma et al. (19). The concentrations of interleukin-6 (IL-6), interleukin-12 (IL-12) and tumor necrosis factor-alpha (TNF α) were determined by quantitative enzyme immunoassay (ELISA), using a commercial kit (MyBioSource, San Diego, CA, USA) according to previously issued papers (20-22).

Statistical analysis

All data were analyzed using one-way analysis of variance (ANOVA), using Statistical Package for Social Sciences software, version 16.0 (SPSS Inc., Chicago, IL). The level of significance between groups was determined by Duncan's post hoc test. The results are expressed as means \pm standard error (SE). A *p*-value of less than 0.05 was considered statistically significant.

Results

There was no significant difference between the clinical observations of goats in G1 after allicin administration and those of control goats. However, goats in G2 represented variable clinical symptoms that appeared shortly after seven days of infection with *E. coli* as dull, depression, soft feces to mild diarrhea. The mean rectal temperature and heart and respiration rates of these animals were significantly increased on the 7th day (41.23 ± 0.14 °C, 104.0 ± 3.78 /min and 37.33 ± 1.45 /min, respectively) and then returned to normal on the 28th day (39.13 ± 0.12 °C, 92.00 ± 3.05 /min and 27.33 ± 1.2 /min, respectively) (Table 1).

Allicin administration had no significant influence on the hematological parameters (Hb, PCV and RBCs) in prophylactic and treated groups in comparison with control group throughout different experiment periods ($P > 0.05$). There was a significant increase in WBCs and neutrophil count on the 7th, 14th, 28th and 42th days of the experiment in prophylactic and treated groups ($P < 0.05$) then they gradually decreased until returning to the normal range on the 56th day (WBCs, G1, 23.00 ± 0.57 ; G2, 24.00 ± 0.57 vs. control G3, $23.23 \pm 0.39/10^3$ /mL; $P > 0.05$, while neutrophils; G1, 5.6 ± 0.3 ; G2, 6.2 ± 0.3 vs. control G3, $5.6 \pm 0.1/10^3$ /mL; $P > 0.05$) (Table 2).

Total proteins, albumin and globulin were significantly increased in G1 after allicin administration on 7th day (TP, 7.4 ± 0.08 vs. control 6.2 ± 0.03 ; Alb, 3.7 ± 0.1 vs. control 3.2 ± 0.1 and finally globulin, 3.6 ± 0.2 vs. control 3.0 ± 0.1) and this increase continued till 28th day of the study. While they significantly decreased in G2 after *E. coli* inoculation on 7th day and gradually increased on 14th and 17th day of study.

The level of these parameters returned similar to the control on 28th day ($P > 0.05$). Malondialdehyde levels were higher in both groups following *E. coli* inoculation on the 14th day in G1 (10.6 ± 0.2 vs. G3, 6.1 ± 0.1) and on day 7th in G2 (10.4 ± 0.2 vs. control, 6.1 ± 0.1) then decreased significantly till it returned to the normal range on the 28th day ($P > 0.05$). Total antioxidant capacity was increased significantly on 7th day in the G1 but it fell significantly in G2 during the same time period then increased significantly on both groups till 28th day and became within the normal range thereafter (Table 3).

In comparison to the control group, allicin administration elevated the immunological measures (IgG, IgM and IgA) in both research groups, and this elevation was starting to be elevated significantly on 7th day in G1 then highly significant increased on the 14th day in G1 after *E. coli* inoculation, which continued to be significantly elevated until the day 28 of the trial. While in the G2 the increase values of immunoglobulins started to be significant on 14th day after oral administration of allicin and continued until day 42th of study ($P < 0.05$) (Table 4).

The release of IL-6, IL-12, and TNF- α was considerably significantly higher in both infected groups than in the control one, from 7th day of the trial in G1 and continued to 28th day while start to be marked increase in 14th day in G2 and this increase continued till 42th day of the study then reduce the level of inflammatory markers to normal level as in control group (Table 4).

Discussion

Regarding the clinical symptoms, the increase in body temperature in goats following *E. coli* inoculation was consistent with a previous study in which certain endogenous pyrogens, collectively known as interleukins, are released from activated phagocytic cells and reticuloendothelial cells of the host in response to the inflammation (23). Colibacillosis causes an increase in respiration and heart rates due to elevated body temperature and hypotension induced by *E. coli* endotoxin. According to the obtained results, oral administration of allicin improves the clinical symptoms in goats in both treated groups.

Table 2: The effect of allicin supplement as prophylactic or treatment in goats experimentally infected with *E. coli* O157 on hematological parameter

Hematological parameter	Group 1	Group 2	Group 3	<i>P</i> -value
Hb (g/dL) / day				
0	12.12 ± 0.394	11.91 ± 0.045	11.85 ± 0.202	0.54
7 th	11.66 ± 0.102	11.77 ± 0.145	11.40 ± 0.265	< 0.001
14 th	11.83 ± 0.117	11.75 ± 0.176	11.57 ± 0.176	0.014
17 th	11.79 ± 0.195	11.82 ± 0.199	11.66 ± 0.145	0.013
28 th	11.99 ± 0.062	11.65 ± 0.105	11.73 ± 0.145	0.824
42 th	12.06 ± 0.097	11.85 ± 0.152	11.80 ± 0.153	0.555
56 th	11.79 ± 0.069	11.93 ± 0.328	12.03 ± 0.067	0.045
PCV(%) / day				
0	39.10 ± 0.321	38.90 ± 0.058	38.90 ± 0.115	0.729
7 th	38.47 ± 0.305	38.60 ± 0.379	38.10 ± 0.379	0.612
14 th	38.43 ± 0.233	38.47 ± 0.285	37.17 ± 1.167	0.391
17 th	38.53 ± 0.318	38.69 ± 0.218	37.83 ± 0.167	0.097
28 th	38.62 ± 0.154	38.67 ± 0.088	38.57 ± 0.233	0.918
42 th	38.87 ± 0.161	39.00 ± 0.100	39.17 ± 0.120	0.343
56 th	38.79 ± 0.066	39.25 ± 0.029	38.73 ± 0.328	0.198
RBCs10 ⁶ /mL / day				
0	7.013 ± 0.104	7.133 ± 0.088	7.067 ± 0.120	0.733
7 th	7.100 ± 0.208	7.333 ± 0.203	6.967 ± 0.203	0.483
14 th	6.907 ± 0.103	6.700 ± 0.208	6.567 ± 0.133	0.357
17 th	7.160 ± 0.226	7.333 ± 0.176	6.967 ± 0.219	0.501
28 th	7.007 ± 0.080	7.547 ± 0.195	7.267 ± 0.219	0.174
42 th	6.873 ± 0.072	7.333 ± 0.219	7.033 ± 0.033	0.124
56 th	7.040 ± 0.130	7.163 ± 0.148	7.180 ± 0.144	0.756
WBCs 10 ³ /mL / day				
0	22.93 ± 0.233	22.93 ± 0.088	22.93 ± 0.296	1
7 th	29.00 ± 0.577 ^a	31.33 ± 1.453 ^a	22.83 ± 0.167 ^b	0.001
14 th	34.00 ± 0.577 ^a	31.00 ± 0.577 ^b	23.07 ± 0.233 ^c	< 0.001
17 th	34.00 ± 0.764 ^a	34.27 ± 0.371 ^a	23.00 ± 0.577 ^b	< 0.001
28 th	31.33 ± 0.601 ^a	31.33 ± 0.333 ^a	23.20 ± 0.306 ^b	< 0.001
42 th	27.17 ± 0.441 ^a	25.67 ± 0.667 ^{ab}	24.33 ± 0.441 ^b	0.025
56 th	23.00 ± 0.577	24.00 ± 0.577	23.23 ± 0.393	0.422
Neutrophils 10 ³ /mL / day				
0	5.333 ± 0.333	5.333 ± 0.333	5.667 ± 0.333	0.729
7 th	10.00 ± 0.577 ^a	10.67 ± 0.882 ^a	6.000 ± 0.577 ^b	0.006
14 th	15.00 ± 1.155 ^a	11.00 ± 1.155 ^b	5.500 ± 0.289 ^c	0.001
17 th	21.17 ± 1.014 ^a	17.00 ± 0.577 ^b	5.500 ± 0.289 ^c	< 0.001
28 th	12.00 ± 0.577 ^a	13.67 ± 0.882 ^a	5.333 ± 0.240 ^b	< 0.001
42 th	12.13 ± 0.570 ^a	7.000 ± 0.577 ^b	5.333 ± 0.240 ^b	< 0.001
56 th	5.667 ± 0.333	6.233 ± 0.338	5.633 ± 0.120	0.312

Values are represented as mean ± SEM. Means within the same row carrying different superscripts (a, b, and c) are significant at *P* < 0.05. N.B RBCs expressed as (10⁶/mL); Neutrophils (10³/mL). Hemoglobin (Hb.) g/dL, packed cell volume (PCV) (%), red blood cells (RBCs), white blood cells (WBCs) (10³/mL)

Table 3: The effect of allicin supplement as prophylactic or treatment in goats experimentally infected with *E. coli* O157 on total proteins, albumin, globulin, MDA and TAC

Parameter	Group 1	Group 2	Group 3	P-value
TP (g/dL) / day				
0	6.267 ± 0.067	6.210 ± 0.150	6.217 ± 0.044	0.906
7 th	7.423 ± 0.087 ^a	5.167 ± 0.088 ^c	6.267 ± 0.033 ^b	< 0.001
14 th	7.467 ± 0.203 ^a	6.300 ± 0.058 ^b	6.233 ± 0.120 ^b	0.001
17 th	8.347 ± 0.222 ^a	7.300 ± 0.153 ^b	6.333 ± 0.067 ^c	< 0.001
28 th	7.207 ± 0.058 ^a	7.567 ± 0.240 ^a	6.267 ± 0.133 ^b	0.003
42 th	6.113 ± 0.054	5.910 ± 0.081	6.227 ± 0.166	0.205
56 th	6.133 ± 0.086	6.363 ± 0.134	6.387 ± 0.156	0.369
Alb (g/dL) / day				
0	3.097 ± 0.078	3.140 ± 0.067	3.360 ± 0.204	0.379
7 th	3.767 ± 0.145 ^a	2.767 ± 0.145 ^b	3.267 ± 0.145 ^{ab}	0.008
14 th	3.650 ± 0.104 ^a	3.200 ± 0.115 ^b	3.250 ± 0.087 ^b	0.04
17 th	4.233 ± 0.145 ^a	3.900 ± 0.058 ^a	3.163 ± 0.068 ^b	0.001
28 th	3.833 ± 0.088	3.760 ± 0.288	3.267 ± 0.035	0.119
42 th	3.233 ± 0.083	3.367 ± 0.088	3.407 ± 0.159	0.57
56 th	3.213 ± 0.024	3.280 ± 0.049	3.200 ± 0.115	0.726
Globulin(g/dL) / day				
0	3.170 ± 0.130	3.070 ± 0.153	2.857 ± 0.187	0.416
7 th	3.657 ± 0.219 ^a	2.400 ± 0.153 ^b	3.000 ± 0.153 ^b	0.007
14 th	3.817 ± 0.192 ^a	3.100 ± 0.173 ^b	2.983 ± 0.044 ^b	0.016
17 th	4.113 ± 0.098 ^a	3.400 ± 0.115 ^b	3.170 ± 0.122 ^b	0.002
28 th	3.373 ± 0.116	3.807 ± 0.383	3.007 ± 0.134	0.145
42 th	2.877 ± 0.041	2.543 ± 0.170	2.817 ± 0.017	0.12
56 th	2.920 ± 0.066	3.083 ± 0.153	3.187 ± 0.271	0.612
MDA nmoL/mL / day				
0	6.910 ± 0.485	6.567 ± 0.088	6.493 ± 0.211	0.621
7 th	6.720 ± 0.081 ^b	10.40 ± 0.208 ^a	6.133 ± 0.186 ^c	< 0.001
14 th	10.67 ± 0.240 ^a	10.90 ± 0.557 ^a	6.133 ± 0.176 ^b	< 0.001
17 th	7.900 ± 0.208 ^a	8.233 ± 0.120 ^a	6.100 ± 0.153 ^b	< 0.001
28 th	7.200 ± 0.208	7.300 ± 0.115	6.667 ± 0.240	0.123
42 th	6.867 ± 0.186	7.267 ± 0.145	6.700 ± 0.289	0.239
56 th	6.077 ± 0.253	6.500 ± 0.115	6.700 ± 0.115	0.106
TAC ng/mL / day				
0	13.67 ± 0.333	13.67 ± 0.353	13.67 ± 0.186	1
7 th	15.10 ± 0.208 ^a	11.83 ± 0.167 ^c	13.10 ± 0.208 ^b	< 0.001
14 th	15.20 ± 0.200 ^a	15.07 ± 0.133 ^a	13.07 ± 0.067 ^b	< 0.001
17 th	15.13 ± 0.120 ^a	15.07 ± 0.176 ^a	12.80 ± 0.115 ^b	< 0.001
28 th	15.10 ± 0.208 ^a	14.93 ± 0.067 ^a	13.07 ± 0.176 ^b	< 0.001
42 th	13.37 ± 0.315	12.92 ± 0.186	13.03 ± 0.376	0.579
56 th	13.17 ± 0.120	13.57 ± 0.257	13.10 ± 0.153	0.234

Values are represented as mean ± SEM. Means within the same row carrying different superscripts (a, b, c and d) are significant at $P < 0.05$. Total proteins (TP), albumin (ALB.), malondialdehyde (MDA), total antioxidant capacity (TAC)

Table 4: The effect of allicin supplement as prophylactic or treatment in goats experimentally infected with *E. coli* 0157 on some immunological and inflammatory parameters.

Parameters	Group 1	Group 2	Group 3	P-value
IgG (ng/mL) / day				
0	313.0 ± 13.53	308.7 ± 4.978	310.0 ± 5.774	0.941
7 th	357.3 ± 15.07 ^a	306.7 ± 2.404 ^b	306.3 ± 4.667 ^b	0.012
14 th	436.7 ± 8.819 ^a	376.7 ± 8.819 ^b	317.0 ± 3.786 ^c	< 0.001
17 th	373.7 ± 11.70 ^a	340.0 ± 5.774 ^b	315.0 ± 3.606 ^b	0.005
28 th	372.0 ± 11.37 ^a	341.7 ± 4.410 ^b	310.0 ± 5.292 ^c	0.004
42 th	315.0 ± 2.887 ^b	342.3 ± 3.930 ^a	312.7 ± 3.180 ^b	0.001
56 th	308.7 ± 7.688	309.7 ± 3.480	312.3 ± 4.333	0.889
IgM (ng/mL) / day				
0	144.3 ± 0.882	143.3 ± 2.404	144.0 ± 2.082	0.932
7 th	169.0 ± 6.658 ^a	150.0 ± 1.155 ^b	144.0 ± 1.000 ^b	0.01
14 th	194.3 ± 2.963 ^a	168.3 ± 1.667 ^b	143.3 ± 2.028 ^c	< 0.001
17 th	181.0 ± 2.082 ^a	169.0 ± 2.082 ^b	144.0 ± 0.577 ^c	< 0.001
28 th	179.7 ± 2.186 ^a	171.3 ± 2.404 ^b	148.0 ± 1.155 ^c	< 0.001
42 th	150.7 ± 1.764 ^b	169.3 ± 0.667 ^a	147.0 ± 1.528 ^b	< 0.001
56 th	149.0 ± 0.577	151.0 ± 3.786	146.7 ± 0.882	0.45
IgA (ng/mL) / day				
0	126.3 ± 1.202	126.0 ± 2.000	124.0 ± 0.577	0.482
7 th	143.7 ± 4.410 ^a	129.0 ± 1.528 ^b	124.7 ± 0.333 ^b	0.006
14 th	147.3 ± 5.487 ^a	150.0 ± 3.786 ^a	126.0 ± 1.000 ^b	0.009
17 th	151.3 ± 2.603 ^a	154.0 ± 2.082 ^a	124.7 ± 0.333 ^b	< 0.001
28 th	154.7 ± 1.453 ^a	157.3 ± 1.764 ^a	125.0 ± 1.528 ^b	< 0.001
42 th	129.3 ± 3.180	126.3 ± 1.202	124.7 ± 0.882	0.326
56 th	128.3 ± 2.848	126.7 ± 0.333	125.7 ± 1.453	0.615
IL-6 (pg/mL) / day				
0	82.33 ± 1.856	83.33 ± 0.882	79.33 ± 2.333	0.329
7 th	92.00 ± 1.528 ^a	82.67 ± 0.882 ^b	82.33 ± 2.028 ^b	0.007
14 th	100.3 ± 0.882 ^a	91.67 ± 0.882 ^b	81.33 ± 0.882 ^c	< 0.001
17 th	92.33 ± 1.202 ^b	113.3 ± 4.702 ^a	83.33 ± 0.333 ^b	0.001
28 th	92.67 ± 1.856 ^a	93.67 ± 0.882 ^a	82.33 ± 1.453 ^b	0.003
42 th	82.33 ± 1.667 ^b	93.33 ± 0.882 ^a	82.00 ± 1.528 ^b	0.002
56 th	74.67 ± 2.028 ^b	80.67 ± 1.202 ^a	82.67 ± 0.333 ^a	0.015
IL-12 (pg/mL) / day				
0	82.33 ± 2.404	79.00 ± 2.082	75.67 ± 1.453	0.144
7 th	89.00 ± 0.577 ^a	76.00 ± 0.577 ^b	76.33 ± 1.333 ^b	< 0.001
14 th	102.0 ± 3.055 ^a	89.00 ± 0.577 ^b	76.00 ± 1.155 ^c	< 0.001
17 th	90.00 ± 1.155 ^b	106.7 ± 3.528 ^a	75.33 ± 1.453 ^c	< 0.001
28 th	89.00 ± 0.577 ^b	91.00 ± 0.577 ^a	76.33 ± 0.333 ^c	< 0.001
42 th	78.00 ± 1.000 ^b	90.00 ± 1.155 ^a	73.33 ± 0.882 ^c	< 0.001
56 th	75.50 ± 1.155	73.33 ± 0.882	74.00 ± 1.155	0.4
TNF-α (pg/mL) / day				
0	74.33 ± 1.202	72.33 ± 2.404	71.33 ± 2.906	0.659
7 th	90.50 ± 1.607 ^a	79.00 ± 0.577 ^b	69.33 ± 2.963 ^c	0.001
14 th	108.0 ± 1.528 ^a	101.3 ± 1.764 ^a	70.67 ± 2.906 ^b	< 0.001
17 th	101.0 ± 2.082 ^b	109.3 ± 1.764 ^a	70.67 ± 1.764 ^c	< 0.001
28 th	96.67 ± 2.404 ^a	96.33 ± 2.186 ^a	69.67 ± 1.453 ^b	< 0.001
42 th	93.00 ± 1.528 ^a	92.00 ± 2.082 ^a	69.00 ± 0.577 ^b	< 0.001
56 th	71.00 ± 0.577	70.33 ± 0.882	68.67 ± 2.333	0.55

Values are represented as mean ± SEM. Means within the same row carrying different superscripts (a, b, c and d) are significant at $p < 0.05$. Immunoglobulin (Ig), interleukin (IL), tumor necrosis factor (TNF)

The essential hematological alterations in this study were the increase in total leukocytes and neutrophils in the treatment group (G2), which could be due to infection, immune system problems, or stress (24). The obtained leukocytosis represented by neutrophilia may be attributed to the induced stress during *E. coli* infection, causing the release of endogenous corticosteroids. In harmony with our results, garlic powder supplementation had no positive effect on Hb, PCV, and RBC in finishing pigs (25). Improved hematological parameters could be due to reducing bacterial infection or parasitic infestation or due to improved nutrient supply as a response to allicin supplementation (26, 27).

Higher serum total protein and albumin level were consistent with a previous study (28). A significant increase in globulin concentration may be attributed to tissue injury (29). The substantial increase in globulin in goats following *E. coli* inoculation could be attributed to the pathogenic agents stimulating the immune system (30). The significant increase of MDA on the 14th day in G1 and on the 7th day in G2 may be explained as infectious diseases causing inflammatory reactions associated with enhanced oxidative reactions and limiting antioxidant defense capabilities (31). Excessive lipid peroxidation in plasma and cells could explain these findings. Allicin acts as an antioxidant by trapping radicals when it reacts with free thiol-containing enzymes. Allicin has been proven to scavenge hydroxyl radicals, limit superoxide formation, and inhibit superoxide production (32). The decreased MDA values on the 17th day in both groups and the significant increase of TAC in both groups after allicin administration may be attributed to the antioxidant nature of allicin (33). The results indicated that allicin treatment ameliorated oxidative stress.

Garlic has the ability to boost an animal's immune system. Our findings were consistent with those of Alam et al. (34), who reported that allicin administration has antioxidant, anti-inflammatory, and immunostimulant effects. Allicin induced IgG, IgM and IgA elevation provided evidence for allicin's immunostimulatory effect, which is consistent with its effect on calves (35). Additionally, the obtained results showed that allicin administration improved serum immunoglobulins as immunity markers, showing the

highest improvement of immunity. Higher immunoglobulins could be related to increased cytokine production, which could imply an immunomodulatory effect of allicin (36). This demonstrates the ability of allicin to induce a humoral- and cellular-mediated immune response to decrease inflammatory reaction provoked by infection (36). So, the allicin's capacity to modulate the synthesis of these components may help to alleviate some of the symptoms of infection and to lower disease severity.

Interleukins are certain endogenous pyrogens released by the host's activated phagocytic cells and reticulo-endothelial cells in reaction to inflammation, tissue damage, bacterial toxins, and other illnesses. Cytokines have a crucial role in the inflammatory response and the progression of infection (37). Some cytokines (IL-6, IL-12, and TNF- α), have been shown to increase during infections (38). Allicin stimulates anti-inflammatory effects by stimulating of pro-inflammatory cytokines (36). Garlic or garlic constituents have an immunomodulatory effect on cytokine production. The selected interleukins (IL-6, IL-12, and TNF- α) increased significantly after *E. coli* inoculation. Our finding strongly supported the previous results of Fernández et al. (39), who reported a significant interaction between the microorganisms and cytokine markers. Nevertheless, our results are inconsistent with a previous work (40) which found that allicin had a strong inhibitory effect on the three inflammatory factors, TNF- α , IL6 and IL12. Garlic extract has recently been shown to stimulate TNF- gene production in murine macrophages (41). The present study demonstrated that allicin administration could modulate the immune response in goats toward the bacterial infection, colibacillosis, therefore maintaining the body's defensive mechanisms within normal ranges. Thus, oral administration of allicin preparation may be a practical strategy to increase animal immunity, which benefits profitability in livestock production.

Conclusion

It was concluded that dietary supplementation of allicin with normal ration would be an additional management approach to improve the immunological and antioxidant status of goats, which

would increase their resistance to bacterial infection, particularly colibacillosis.

All of the authors were contributed in the study design and in the writing of the manuscript. The samples were collected by NEA and EMF, who also monitored the animals. The data was analyzed by YHB and MB, and the results were reviewed by AB. The final manuscript was read and approved by all authors.

The authors declare that they have no competing interests.

References

1. Konlan SP, Karikari PK, Ansah T. Productive and blood indices of dwarf rams fed a mixture of rice straw and groundnut haulms alone or supplemented with concentrates containing different levels of sheanut cake. *Pak J Nutr* 2012; 11: 566 – 571.
2. Husain SS. Sustainable genetic improvement of economic traits of Black Bengal goats through selective and crossbreeding. *Bangladesh Agricultural University Research Progress* 1999; 10: 72-80.
3. Rivlin RS. Historical perspective on the use of garlic. *J Nutr* 2001; 131: 951-954.
4. Kaye AD, Nossaman BD, Ibrahim IN, et al. Analysis of responses of allicin, a compound from garlic, in the pulmonary vascular bed of the cat and in the rat. *Eur J Pharmacol* 1995; 276: 21-26.
5. Kamra DN, Agarwal N, Sakthivel PC, et al. Garlic as a rumen modifier for eco-friendly and economic livestock production. *J Appl Anim Res* 2012; 40: 90-96.
6. Pe´ rez-Giraldo C, Cruz-Villaon G, Sanchez-Silos R, et al. In vitro activity of allicin against *Staphylococcus epidermidis* and influence of sub inhibitory concentrations on biofilm formation. *J Appl Microbiol* 2003; 95:709-711.
7. Hashish EA, El Damaty HM, Tartor YH et al. 2016. Epidemiological study of diarrheagenic *Escherichia coli* virulence genes in newborn calves. *Pak Vet J*, 36: 54-58.
8. Gyles CL. *E. coli* in domestic animals and Humans. Wallingford, UK: CAD , 1994.
9. Nguyen TD, Vo TT, Vu-Khac H. Virulence factors in *Escherichia coli* isolated from calves with diarrhea in Vietnam. *J Vet Sci* 2011; 12: 159–164.
10. Elmowalid GA, Ahmad AAM, Hassan MN, et al. Molecular detection of new SHV β -lactamase variants in clinical *Escherichia coli* and *Klebsiella pneumoniae* isolates from Egypt. *Comp Immunol Microbiol Infect Dis* 2018; 60: 35-41.
11. Raetz CRH, C Whitfield. Lipopolysaccharide endotoxins. *Annu Rev Biochem* 2002; 71: 635-700.
12. Tartor YH, Hassan FAM. Assessment of carvacrol for control of avian aspergillosis in intratracheally challenged chickens in comparison to voriconazole with a reference on economic impact. *J Appl Microbiol*. 2017;123(5):1088-1099. doi: 10.1111/jam.13557.
13. Abd El-Aziz NK, Ammar AM, El-Naenaeey EYM, et al. (2021). Antimicrobial and antibiofilm potentials of cinnamon oil and silver nanoparticles against *Streptococcus agalactiae* isolated from bovine mastitis: New avenues for countering resistance. *BMC Vet Res*; 17, 1–14.
14. Rabinkov A, Miron T, Konstantinovski L, et al. The Mode of Action of Allic: Trapping of Radicals and Interaction with Thiol-Containing Proteins. *Biochim Biophys Acta* 1998; 1379: 233–234.
15. Rigobelo EC, Maluta RP, Borges CA, et al. Evaluation of protective effect of probiotic in sheep against experimental infection by *Escherichia coli*. *Afr J Microbiol Res* 2013; 7: 1262-1265.
16. Najar-Nezhad V, Aslani MR, Balali-Mood M. Evaluation of Allicin for the Treatment of Experimentally Induced Subacute Lead Poisoning in Sheep. *Biol Trace Elem Res* 2008; 126:141–147.
17. Kaneko JJ, Harvey JW, Bruss ML. Clinical biochemistry of domestic animals, 5th edn. Academic Press, Inc, California, USA, 1997.
18. Koracevic D, Koracevic G, Djordjevic V, et al. Method for the measurement of antioxidant activity in human fluids. *J Clin Pathol* 2001; 54: 356-361.
19. Toma VA, Farcas AD, Roman I, et al. Comparative in vivo effects of hemoglobin-based oxygen carriers (HBOC) with varying prooxidant and physiological reactivity. *PLoS ONE* 2016; 11:1-16.
20. Wong GG, Clark SC. Multiple actions of interleukin 6 within a cytokine network. *Immunol Today* 1988; 9:137–139.
21. Grassi J, Roberge CJ, Frobert Y. Determination of IL-10, IL-1 β and IL-2 in biological media using specific enzyme immunometric assay. *Immunol Rev* 1991; 119: 125-145.
22. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. *Nature* 1985; 316: 552–554.
23. Van Miert A. Influence of febrile diseases on the pharmacokinetics of veterinary drugs. *Ann Rech Vet* 1990; 21 (1): 11-28.
24. Bagby GC. Leucopenia and leucocytosis. In: Goldman L, Ausiello D, eds. *Cecil Medicine*. 23rd ed. Philadelphia. Pa: Saunders Elsevier, 2007:173.
25. Yan I, Meng QW, Ao X, et al. Effects of fermented garlic powder supplementation on growth performance, blood characteristics and meat quality in

- finishing pigs fed low-nutrient-density diets. *Livest Sci* 2011; 137: 255–259.
26. Fawzi E, Elsohaby I. Prevalence of Gastrointestinal Nematodes and the Role of Allicin in Treatment of Cattle in Sharkia Governorate. *Zagazig Veterinary Journal* 2017; 45: 109-117.
27. Zhong R, Xiang H, Long Cheng L, et al. Effects of feeding garlic powder on growth performance, rumen fermentation, and the health status of lambs infected by gastrointestinal nematodes. *Animals* 2019; 9: 102.
28. Kholif SM, Morsy TA, Abdo MM, et al. Effect of supplementing lactating goats rations with garlic, cinnamon or ginger oils on milk yield, milk composition and milk fatty acids profile. *J Life Sci* 2012; 4: 27-34.
29. Brito Galvao JF, Center SA. Fluid, electrolyte, and acid-Base disturbances in liver disease. In: *Fluid, electrolyte, and acid-base disorders in small animal practice*, Fourth Edition, Elsevier. 2012: 456-499.
30. Abd El-Raof YM, Hassan HY. Ultrasonography and other aids for calf pneumonia diagnosis. 5th Sci. Cong. Egy. Soci. Cattle Dis. 1999; 20-30 Nov. Assuit, Egypt.
31. Behrman HR, Kodman PH, Preston SI, et al. Oxidative stress and the ovary. *J Soc Gynecol Investig* 2001; 8: 540-542.
32. Miron T, Rabinkov A, Mirelman D, et al. The Mode of Action of Allicin: Its Ready Permeability through Phospholipid Membranes May Contribute to Its Biological Activity. *Biochim Biophys Acta* 2000; 1463: 20–30.
33. Abdel-Daim MM, Abushouk AI, Donia T, et al. The nephroprotective effects of allicin and ascorbic acid against cisplatin-induced toxicity in rats. *Environ Sci Pollut Res Int* 2019; 26: 13502– 13509.
34. Alam RTM, Fawzi EM, Alkhalf MI, et al. Anti-inflammatory, immunomodulatory, and antioxidant activities of allicin, norfloxacin, or their combination against *Pasteurella multocida* infection in male New Zealand rabbits. *Oxid Med Cell Longev* 2018; 4: 1-10.
35. Pekmezci D, Cakiroglu D. Investigation of immunomodulatory effects of levamisole and vitamin E on immunity and some blood parameters in newborn Jersey calves. *Vet Res Commun* 2009; 33: 711-721.
36. Arreola R, Quintero-Fabián S, López-Roa RI, et al. Immunomodulation and anti-inflammatory effects of garlic compounds. *J Immunol Res* 2015: 401630.
37. Gómez-Laguna J, Salguero FJ, Barranco I, et al. Cytokine expression by macrophages in the lung of pigs infected with the porcine reproductive and respiratory syndrome virus. *J Comp Pathol.* 2010; 142:51-60.
38. Notebaert S, Demon D, Vanden Berghe T, et al. Inflammatory mediators in *Escherichia coli*-induced mastitis in mice. *Comp Immunol Microbiol Infect Dis* 2008; 31: 551-565.
39. Fernández S, Galapero J, Rey J, et al. Cytokines Study in Lungs Infected with *Pasteurellaceae* and *Mycoplasma spp.* from Fattening Lambs. *J Med Microbiol Immunol* 2018; 2:1.
40. Gu X, Haishan Wu, Peiliang Fu. Allicin Attenuates Inflammation and Suppresses HLA-B27 Protein Expression in Ankylosing Spondylitis Mice. *Biomed Res Int* 2013; ID 171573.
41. Sung J, Harfouche Y, De La Cruz M, et al. Garlic (*Allium sativum*) stimulates lipopolysaccharide-induced tumor necrosis factor-alpha production from J774A.1 murine macrophages. *Phytother Res* 2015; 29: 288-294.